News Release: IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19

by Shana Cristoferi | Mar 18, 2020 | IMV Inc., News

See original release here FOR IMMEDIATE RELEASE Dartmouth, Nova Scotia, March 18, 2020 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based...

News Release: IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

by Shana Cristoferi | Feb 25, 2020 | IMV Inc., News

See original release here February 25, 2020 at 3:05 AM EST First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor 79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions 37% achieved...

IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

by Shana Cristoferi | Sep 5, 2019 | IMV Inc., News

Read original article here September 4, 2019 at 7:05 AM EDT DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–Sep. 4, 2019– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and...

ENTREVESTOR: Atlantic Canadian startups eyeing the stock market like never before

by Shana Cristoferi | Jun 27, 2019 | Appili Therapeutics, IMV Inc., News, SONA NanoTech

Read full Entrevestor article here The stock market is looming larger in the Atlantic Canadian startup community than it ever has before, as several leading companies are choosing public markets as the best option to secure long-term financing. Just in the past week,...

First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients

by administrator | Jan 17, 2019 | IMV Inc., Members, News

Read original release here January 17, 2019 at 7:05 AM EST DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the...

IMV Inc. Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia

by administrator | Sep 4, 2018 | IMV Inc., News

See original article here DARTMOUTH, Nova Scotia, Sept. 04, 2018 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, celebrated its grand opening today of its new facilities in Dartmouth, Nova Scotia. Frederic Ors,...